This 6-month randomized controlled trial included an intervention group who supplemented with 1.2 grams of MLT (containing 91.8 mg of magnesium) daily for 12 weeks after surgery and a control group who received a matched placebo.

The primary outcomes were incidence of symptomatic pain (score of 3 or higher on a Visual Analog Scale) and pain severity, as measured with the Short Form McGill Pain Questionnaire (SF-MPQ). The secondary outcomes included anxiety, depression, sleep quality, and cognitive status, as measured by the Generalized Anxiety Disorder Scale, Patient Health Questionnaire-9, Pittsburgh Sleep Quality Index, and Telephone Interview for Cognitive Status, respectively.

All outcomes were assessed at baseline (prior to surgery), 1 month, 3 months (intervention conclusion), and 6 months, with the exception of TICS (assessed only at 6 months).

Magnesium for persistent pain after breast cancer surgery Original paper